Objective: Longitudinal studies support a prospective relationship between weight suppression (WS) and bulimic syndrome (BN-S) maintenance. Although biobehavioral mechanisms have been proposed to explain this link, such mechanisms have yet to be identified. Given that weight loss would reduce leptin levels which may influence eating, this study examined whether reduced leptin levels mediate the link between greater WS and longer illness duration. Results: Significant associations were found among greater WS, lower leptin concentrations, and longer duration of illness. Mediation analyses using bootstrapping procedures indicated all paths were significant and that leptin mediated the link between WS and illness duration. An alternative model in which longer illness duration contributed to leptin, via greater WS, was not supported.
| I N TR ODU C TI ON
Women with bulimia nervosa (BN) have greater weight suppression (WS) compared to controls (Bodell & Keel, 2015; Davis, Holland, & Keel, 2014; Van Son, van der Meer, & Van Furth, 2013) , reflecting a greater difference between their highest prior weight and current weight (Lowe, 1993) . WS prospectively predicts illness maintenance in BN (Butryn, Lowe, Safer, & Agras, 2006; Lowe et al., 2011) and bulimic syndromes (BN-S) more broadly (Bodell, Brown, & Keel, 2017; Keel & Heatherton, 2010) ; however, few studies have examined mediators of the association between WS and illness duration.
Weight loss contributes to reduced leptin concentrations (Rosenbaum et al., 1997; Wolfe, Jimerson, Orlova, & Mantzoros, 2004) .
Therefore, greater WS in BN could explain reduced leptin concentrations found in BN compared to controls in several studies (Jimerson, Wolfe, Carroll, & Keel, 2010; Monteleone, Di Lieto, Tortorella, Longobardi, & Maj, 2000; Monteleone, Fabrazzo, Tortorella, Fuschino, & Maj, 2002) 1 . Supporting this hypothesis, we recently found a significant association between greater WS and lower leptin concentrations in women with BN (Bodell & Keel, 2015) .
Furthermore, prior research found cross-sectional associations between lower leptin concentrations and longer illness duration in BN (Monteleone, Martiadis, Colurcio, & Maj, 2002) . Leptin plays a key role in homeostatic regulation of weight through its modulation of satiation (Davis et al., 2011) . Thus, reduced leptin could maintain binge eating in 1 The influence of weight loss on leptin may reflect reduced body fat in BN compared to control participants at equivalent BMI or a defensive response to recent weight loss in BN even when no difference in body fat exists. Prior studies do not permit conclusions as to the underlying reason for observed differences. BN-S. Additionally, circulating leptin influences hedonic regulation of food intake and other rewarding behaviors by crossing the blood-brain barrier where it binds to leptin receptors and inhibits firing of dopamine neurons in the ventral tegmental area (Hommel et al., 2006) . Thus, reduced leptin could contribute to BN-S maintenance via increased reinforcement of binge eating, purging, or both (Davis et al., 2011) .
Taken together, leptin could mediate associations between WS and BN-S maintenance via homeostatic mechanisms, hedonic mechanisms, or both. Yet, no study has examined whether leptin mediates associations between WS and BN-S maintenance.
The current study sought to examine associations among WS, leptin, and illness duration in BN-S. We predicted that greater WS would be associated with lower leptin and both would be associated with longer illness duration. Further, we hypothesized that the association between greater WS and longer illness duration would be mediated by reduced leptin levels. We also tested a plausible alternative model in which reduced leptin is a consequence of longer illness duration by examining whether WS mediated the association between longer illness duration and leptin. . Racial/ethnic diversity was, 71% white, non-Hispanic, 17% African American, 6% Asian, and 6% Hispanic.
| Procedures
As part of a larger study, participants completed clinical interviews and self-report questionnaires (visit 1), an ad lib test meal (visit 2), and measurement of gastric emptying and gut peptide responses to a standardized test meal with a placebo and medication (visits 3 and 4), with at least 48 h between visits. Data for the current report come from participants recruited in Tallahassee, FL, in whom WS and leptin assessments were completed. This study was reviewed and approved by the Human Subjects Committee of the IRB at Florida State University, and participants completed informed consent prior to study participation.
| Clinical assessments
Eating disorder diagnosis and symptoms were established with the Eating Disorder Examination (EDE) (Fairburn & Cooper, 1993) . Interrater reliability and internal consistency was high (j 5 .90 for diagnoses of BN, PD, vs. control, and r > .97 across EDE scales) and a 5 .96 for EDE total score.
Lifetime eating disorder diagnoses and lifetime and current diagnoses of other Axis I disorders were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-1) (First, 1995) . The primary use of the SCID was to assess eligibility inclusion and exclusion criteria. In addition to excluding current disorders influencing weight or appetite in all participants, women with PD could not have a history of DSM-IV anorexia nervosa (AN), BN, binge-eating disorder (BED), or recurrent objective binge episodes (OBEs). Women with DSM-5 BN could not have a history of DSM-IV AN. Interrater reliability across SCID-I diagnoses was high, with j > .90 for current and lifetime diagnoses.
WS and illness duration were measured using the Oxford Risk Factor Interview 2.3 Obesity Risk Items (RFI) (Fairburn, Welch, Doll, Davies, & O'Connor, 1997) . Participants provided their highest lifetime weight for their current height. Studies have found high correlations (r values .85) between recalled and objectively measured weight in both community (Tamakoshi et al., 2003) and eating disorder samples (Swenne, Belfrage, Thurfjell, & Engstrom, 2005) . The difference between highest prior weight and currently measured weight was used to calculate WS, consistent with its definition in previous studies (Bodell & Keel, 2015; Butryn et al., 2006; Carter, McIntosh, Joyce, & Bulik, 2008; Keel & Heatherton, 2010; Lowe et al., 2011) . On the RFI, index age represents onset of full eating disorder criteria. The difference between current age and index age was used to calculate BN-S duration.
| Leptin assessment
Fasting blood samples were drawn on a separate day between 7:45 and 8:15 a.m. With the exception of hormonal contraceptives, participants were free from all medications for a week and instructed not to consume alcohol or recreational drugs 72 h before these assessments.
Blood samples were collected into prechilled EDTA vacutainers with 150 lL of ready-to-use aprotinin solution (Sigma #A6279) for 3 mL of blood and gently mixed into solution before being centrifuged at 48C to separate plasma. Leptin levels in plasma were determined using 
| Data analyses
Following correlations to examine bivariate associations, structural equation models were used to test mediation. Specifically, bootstrapping procedures were used with 1,000 bootstrap resamples to test the 2 At the time of study initiation, the DSM-5 workgroup had presented proposed revisions to BN criteria for the DSM-5, which were subsequently adopted (APA, 2013), permitting the study to utilize DSM-5 criteria from inception. 
| R E SU LTS
Correlations for BMI, WS, leptin, and symptom severity and illness duration appear in Table 1 . As expected, BMI was not significantly cor- A mediation analysis tested whether the association between WS and illness duration was mediated by leptin. All paths of the model were significant, and the bias corrected 95% confidence interval for the indirect path did not include zero (0.01-0.32), indicating that leptin mediated associations between WS and duration of illness (see Figure 1a) . Because data were cross-sectional, we ran an alternative model to test the indirect effect of illness duration via WS on leptin. Conceptually, this model posits that longer illness duration contributes to greater WS, which then contributes to lower leptin levels. However, this model was not supported because the 95% confidence interval for the indirect path included zero (-0.007 to 0.001) (see Figure 1b) . No other models were considered plausible given research demonstrating that lower leptin contributes to increased food intake and weight (Davis et al., 2011) , which would reduce WS (a direction opposite to that observed).
| D ISC USSION
To our knowledge, this is the first study to test whether the effects of WS on illness duration may be mediated by alterations in circulating leptin. Thus, independent replication of our findings is important before firm conclusions may be drawn. Our mediation analyses suggested that the association between WS and illness duration was statistically mediated by reduced leptin levels. An alternative model, in which the association between illness duration and leptin was mediated by WS, was Our prior investigation of food reward value in BN supported a significant association between WS and leptin and between WS and greater willingness to work for food as a reward (Bodell & Keel, 2015) ; however, leptin was not significantly associated with our behavioral measure of reward value. Of note, within that study, there was a small association in the expected direction (r 5 2.13 and 2.11) in both the full sample and in those with BN, respectively. Thus, WS may be linked to greater food reward via leptin, but effects may require a larger sample with a greater range of severity for adequately powered tests of associations.
This study benefited from several methodological strengths. We utilized measures with strong psychometric properties and participants were repeatedly assessed for BMI across visits to ensure weight stability. This represents a particular strength for evaluation of WS as current findings more likely reflect the impact of sustained maintenance of weight below a previously higher weight rather than recent weight fluctuations. This may have greater relevance for understanding factors that contribute to illness maintenance over longer periods of time (Bodell et al., 2017; Keel & Heatherton, 2010 (Bodell et al., 2017; Butryn et al., 2006; Keel & Heatherton, 2010; Lowe et al., 2011) . Further, a model in which we examined whether illness duration contributed to reduced leptin via WS was not supported. Moreover, cross-sectional support is an important first step before undertaking more resource-intensive longitudinal or experimental designs. Our measure of illness duration did not distinguish between individuals who followed an unremitting course and those who remitted and relapsed, and our measure of WS did not include body fat percentage, the period of time over which weight loss occurred, or how long it had been maintained. Finally, some findings may not have achieved statistical significance due to limited power to detect smaller effect sizes.
In summary, findings offer insight into the role leptin may play in the link between WS and illness maintenance for BN-S. Given that complex behavioral symptoms are likely to emerge from an interplay of multiple factors, each exerting a relatively small effect, future research should examine these links longitudinally in larger and more diverse samples. Importantly, even if future studies find that duration of illness drives reduced leptin, these alterations may contribute to a vicious cycle. Identifying new targets for intervention could enhance treatment outcomes in BN-S.
